Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens

Gynecologic Oncology

Volumn 68, Issue 2, 1998, Pages 178-182

  Roland, P Y ^a   Barnes, M N ^a   Niwas, S ^a   Robertson, M W ^a   Alvarez, R ^a   Austin, J M ^b   Kilgore, L C ^a   Partridge, E E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Southern Gynecologic Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; LUTETIUM; MONOCLONAL ANTIBODY; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARIECTOMY; OVARY CARCINOMA; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0032007190     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4909     Document Type: Article

References (14)

1. McGuire W, Hoskins W, Brady M, Kucera P, Partridge E, Look K, Clarke-Pearson D, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med. 334:1996;1-6.
2. Neijt J, Huinink T, van der Burg M, van Oosterom A, Willemse P, Vermorken J, van Lindert A, Heintz A, Aartsen E, van Lent M, Trimbos J, de Meijer A. Long-term survival in ovarian cancer: Mature date from the Netherlands Joint Study Group for ovarian cancer. Eur J Cancer. 27:1991;1367-1372.
3. Hainsworth J, Grosh W, Burnett L, Jones H, Wolff S, Greco F. Advanced ovarian cancer: Long term results of treatment with intensive cisplatin based chemotherapy of brief duration. Ann Intern Med. 108:1988;165-170.
4. Rubin S. Appendix I: definitions of response. Chemotherapy of Gynecologic Cancer. 1996;Lippincott-Raven, Philadelphia. p. 187.
5. 177. Gynecol Oncol. 65:1997;94-101.
6. Christian M, Trimble E. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol. 55:1994;S143-S150.
7. Thigpen J, Blessing J, Ball H, Hummel S, Barrett R. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group Study. J Clin Oncol. 12:1994;1748-1753.
8. Trimble E, Adams J, Vena D, Hawkins M, Friedman M, Fisherman J, Christian M, Canetta R, Onetto N, Hayn R, Arbuck S. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Insititue treatment referral center 9103. J Clin Oncol. 11:1993;2405-2410.
9. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis J. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
10. Gore M, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 36:1990;207-211.
11. de Gramont A, Drolet Y, Varette C, Louvet C, Gonzalez-Canall G, Krulik M, Cady J, Pigne A, Marpeau L, Barrat J. Survival after second-look laparotomy in advanced ovarian epithelial cancer. Eur J Cancer Clin Oncol. 25:1989;451-457.
12. Podczaski E, Manetta A, Kaminski P, Ricelli A, Larson J, DeGeest K, Mortel R. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. Gynecol Oncol. 36:1990;43-47.
13. Creasman W. Second-look laparotomy in ovarian cancer. Gynecol Oncol. 55:1994;S122-S127.
14. Lippman S M, Alberts D S, Slymen D J, Weiner S, Aristizabal S A, Luditch A, Davis J R, Surwit E A. Second-look laparotomy in epithelial ovarian carcinoma: Prognostic factors associated with survival duration. Cancer. 61:1988;2571-2577.